NUVB — Nuvation Bio Inc. stock price, charts and financials

Latest market price

6.44

+0.28+4.55%

Overview Short InterestFilings

NUVBQT66Nuvation Bio Inc.·NYSE

Overview Short InterestFilings

6.44+4.55%

Earnings

Up 4.5% — Earnings due 2026-08-06 — pre-report positioning.

Medium confidence

Loading chart...

Signal & projected range

Short-squeeze setupHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

HRMY+8.93%$38.78 SION+1.38%$49.94 SLS+5.26%$11.81 BCRX+2.38%$9.02 PVLA+7.96%$151.99 VERA-7.07%$29.95 PGEN-1.21%$6.53 MLYS+2.79%$26.50

Snapshot

Index	-	P/E	-	EPS (ttm)	-0.43	Insider Own	43.75%	Shs Outstand	347.20M	Perf Week	-3.74%

Market Cap	2.24B	Forward P/E	-	EPS next Y	-0.24	Insider Trans	-0.33%	Shs Float	253.59M	Perf Month	15.00%

Enterprise Value	1.71B	PEG	-	EPS next Q	-	Inst Own	-	Short Float	21.95%	Perf Quarter	46.03%

Income	-147.00M	P/S	15.64	EPS this Y	19.96%	Inst Trans	-	Short Ratio	9.29	Perf Half Y	14.39%

Sales	143.00M	P/B	6.99	EPS next Y	29.19%	ROA	-23.92%	Short Interest	55.67M	Perf YTD	-28.12%

Book/sh	0.92	P/C	4.19	EPS next 5Y	-	ROE	-44.10%	52W High	9.75 -33.95%	Perf Year	188.79%

Cash/sh	1.54	P/FCF	-	EPS past 3/5Y	-	ROIC	-27.90%	52W Low	2.18 195.41%	Perf 3Y	268.00%

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-	Gross Margin	91.64%	Volatility	5.45% 6.06%	Perf 5Y	-23.33%

Dividend TTM	-	EV/Sales	11.97	EPS Y/Y TTM	79.62%	Oper. Margin	-104.99%	ATR (14)	0.39	Perf 10Y	-

Dividend Ex-Date	-	Quick Ratio	7.24	Sales Y/Y TTM	1687.50%	Profit Margin	-102.06%	RSI (14)	57.13	Recom	2.20

Dividend Gr. 3/5Y	-	Current Ratio	7.44	EPS Q/Q	106.25%	SMA20	3.44%	Beta	1.49	Target Price	20.00

Payout	0.00%	Debt/Eq	0.04	Sales Q/Q	2666.67%	SMA50	14.46%	Rel Volume	0.72	Prev Close	6.16

Employees	307	LT Debt/Eq	0.01	Earnings	Aug 06	SMA200	12.44%	Avg Volume	6.45M	Price	6.44

IPO Date	Aug 26, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	135.66% 25.68%	Net Debt/EBITDA	0.89	Volume	4,651,600	Change	4.55%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Jul-27-26	Reiterated	HC Wainwright & Co.	Buy	$17 → $21
Jul-07-26	Reiterated	RBC Capital	Outperform	$12 → $19
Jan-27-26	Reiterated	Truist Financial		$11 → $13
Jan-21-26	Reiterated	RBC Capital	Outperform	$5.00 → $12
Jan-12-26	Reiterated	HC Wainwright & Co.	Buy	$18 → $17
Jan-07-26	Reiterated	UBS		$10
Dec-11-25	Reiterated	HC Wainwright & Co.	Buy	$10 → $18
Dec-01-25	Reiterated	HC Wainwright & Co.	Buy	$7.00 → $10
Nov-24-25	Initiated	Truist	Buy	$11
Nov-20-25	Reiterated	JMP Securities	Market Outperform	$8.00 → $10

Latest News

Aug-04-26

Aug-04-2608:00AM

Nuvation Bio to Present New Subgroup Analyses of Pivotal Data for IBTROZI® (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congressesprnewswire.com

Aug-03-26

Aug-03-2611:35AM

4 Biotech Stocks Likely to Outpace Q2 Earnings Estimateszacks.com

Jul-30-26

Jul-30-2611:06AM

Nuvation Bio Inc. (NUVB) Expected to Beat Earnings Estimates: Should You Buy?zacks.com

Jul-29-26

Jul-29-2610:56AM

Wall Street Analysts See a 94.32% Upside in Nuvation Bio (NUVB): Can the Stock Really Move This High?zacks.com

Jul-27-26

Jul-27-2608:21AM

HC Wainwright & Co. Maintains Buy on Nuvation Bio, Raises Price Target to $21Benzinga

Jul-22-26

Jul-22-2604:05PM

Nuvation Bio to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026prnewswire.com

Jul-21-26

Jul-21-2611:10AM

Nuvation Bio (NUVB) Soars 7.9%: Is Further Upside Left in the Stock?zacks.com

Jul-20-26

Jul-20-2611:44AM

Why Is Nuvation Bio Stock Gaining Monday?Benzinga

08:00AM

Nuvation Bio Announces Positive Updated Phase 2 Data and Expansion of Safusidenib Clinical Program with Two New Studies to Explore Broad Spectrum of IDH1-Mutant Gliomaprnewswire.com

Jul-07-26

Jul-07-2612:18PM

RBC Capital Maintains Outperform on Nuvation Bio, Lowers Price Target to $19Benzinga

Jul-06-26

Jul-06-2605:09PM

Nuvation Bio Inc. Announces Full Exercise of Greenshoe Option in $287.5 Million Convertible Senior Notes Offeringprnewswire.com

Jun-29-26

Jun-29-2607:19PM

Nuvation Bio Stock Is Up 190% Despite Recent Pressure. Should Investors Care About This $753,000 Insider Sale?fool.com

08:00AM

Nuvation Bio Announces Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated in the United Kingdomprnewswire.com

Jun-25-26

Jun-25-2609:36AM

Is GSK Quietly Becoming An Oncology PowerhouseSeekingAlpha

08:08AM

H.B. Fuller, Trip.com, Hertz Global And Other Big Stocks Moving Lower In Thursday Pre-Market SessionBenzinga

Company

Nuvation Bio Inc. functions as a clinical-stage biopharmaceutical enterprise committed to discovering and advancing therapeutic solutions for oncological conditions. Its foremost experimental compound, NUV-422, is a small molecule designed to inhibit cyclin-dependent kinases (CDK)2, CDK4, and CDK6. The company's development pipeline further encompasses NUV-868, an orally administered, selective small molecule BET inhibitor that epigenetically influences proteins critical for tumor proliferation and cellular differentiation; NUV-569, a unique oral small molecule targeting the Wee1 kinase to facilitate DNA damage repair; and NUV-1182, an antagonist of adenosine receptors. Additionally, Nuvation Bio is progressing a sophisticated drug-drug conjugate (DDC) platform, engineered to deliver a poly ADP ribose polymerase (PARP) inhibitor in conjunction with existing anti-cancer warheads, particularly for the treatment of ER-positive breast and ovarian cancers. Established in 2018, the firm was initially named RePharmation Inc. before rebranding as Nuvation Bio Inc. in April 2019, and its central operations are based in New York, New York.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	143	63	8	0	0	0	0	0	0
Cost of Goods Sold Incl. D&A	12	8	7	0	0	0	0	0	0
Gross Profit	131	54	1	0	0	0	0	0	0
Selling, General and Administrative Excl. Other	153	152	69	29	32	24	11	7	1
Research and Development	125	115	524	71	88	69	33	25	0
Other Operating Expense	3	1	0	0	0	0	-1	0	0
Operating Income	-150	-213	-593	-100	-120	-93	-44	-32	-1
Interest Expense	21	14	0	0	0	0	0	0	0
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	24	22	25	24	16	6	2	-1	0
Net Income Before Taxes	-147	-205	-568	-76	-104	-87	-42	-34	-1
Income Taxes	0	0	0	0	0	0	0	0	0
Consolidated Net Income	-147	-205	-568	-76	-104	-87	-42	-34	-1
Net Income From Continuing Operations	-147	-205	-568	-76	-104	-87	-42	-34	-1
Net Income	-147	-205	-568	-76	-104	-87	-42	-34	-1
EPS (Recurring)	-0.42	-0.60	-2.11	-0.35	-0.48	-0.44	-0.19	-0.16	-0.01
EPS (Basic, Before Extraordinaries)	-0.42	-0.60	-2.11	-0.35	-0.48	-0.44	-0.19	-0.16	-0.01
EPS (Diluted)	-0.43	-0.60	-2.11	-0.35	-0.48	-0.44	-0.19	-0.16	-0.01
EBITDA	-129	-189	-567	-76	-104	-87	-42	-32	0
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—	—	—	—
Price To Sales Ratio	15.63	48.64	89.44	—	—	—	—	—	—
Gross Margin	91.61	85.71	12.50	—	—	—	—	—	—
Operating Margin	-104.90	-338.10	-7,412.50	—	—	—	—	—	—
Net Margin	-102.80	-325.40	-7,100.00	—	—	—	—	—	—
Shares Outstanding	347	342	269	219	217	198	218	207	184
Market Capitalization	2,235	3,064	716	331	417	1,683	2,551	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Sauvage Philippe	Chief Financial Officer	Jul 15 '26	Option Exercise	2.17	40,000	86,800	54,131	Jul 17
Markel Stacy	CHIEF PEOPLE OFFICER	Jun 23 '26	Option Exercise	1.83	125,000	229,250	157,591	Jun 24
Wentworth Kerry	CHIEF REGULATORY OFFICER	Jun 23 '26	Sale	6.02	63,000	379,191	53,000	Jun 24
Sauvage Philippe	Chief Financial Officer	Jun 23 '26	Option Exercise	2.17	47,668	103,440	60,341	Jun 24
Sauvage Philippe	Chief Financial Officer	Jun 23 '26	Sale	6.01	47,668	286,370	12,673	Jun 24
Markel Stacy	CHIEF PEOPLE OFFICER	Jun 23 '26	Sale	6.03	125,000	753,188	32,591	Jun 24
Wentworth Kerry	CHIEF REGULATORY OFFICER	Jun 23 '26	Option Exercise	2.93	63,000	184,590	116,000	Jun 24
Mashal Robert	Director	Jun 09 '26	Buy	4.73	25,000	118,250	225,000	Jun 11
Wentworth Kerry	CHIEF REGULATORY OFFICER	Apr 17 '26	Option Exercise	2.93	36,750	107,678	89,750	Apr 21
Wentworth Kerry	CHIEF REGULATORY OFFICER	Apr 17 '26	Sale	5.01	36,750	184,279	53,000	Apr 21
Liu Dongfang	CHIEF MEDICAL OFFICER	Apr 17 '26	Option Exercise	1.94	50,000	97,000	68,000	Apr 21
Liu Dongfang	CHIEF MEDICAL OFFICER	Apr 17 '26	Sale	5.02	50,000	251,000	18,000	Apr 21
Wentworth Kerry	CHIEF REGULATORY OFFICER	Apr 06 '26	Option Exercise	1.91	200,000	381,000	253,000	Apr 08
Wentworth Kerry	CHIEF REGULATORY OFFICER	Apr 06 '26	Sale	4.52	200,000	903,560	53,000	Apr 08
Liu Dongfang	CHIEF MEDICAL OFFICER	Dec 01 '25	Option Exercise	2.93	150,000	439,500	168,000	Dec 03

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.